News

Biogen News Releases and Company Statements

Media Contacts
US Media Relations
Europe Media Relations
Japan Media Relations
January 7, 2026
Biogen to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026
January 6, 2026
Biogen to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations